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Abstract
Generative Adversarial Networks (GANs) represent a promising class of generative
networks that combine neural networks with game theory. From generating realistic
images and videos to assisting musical creation, GANs are transforming many
fields of arts and sciences. However, their application to healthcare has not been
fully realized, more specifically in generating electronic health records (EHR)
data. In this paper, we propose a framework for exploring the value of GANs in
the context of continuous laboratory time series data. We devise an unsupervised
evaluation method that measures the predictive power of synthetic laboratory test
time series. Further, we show that when it comes to predicting the impact of
drug exposure on laboratory test data, incorporating representation learning of the
training cohorts prior to training GAN models is beneficial.
1 Introduction
Since the development of the Generative Adversarial Networks (GANs) framework described by
Goodfellow et al. [5] in 2014, about 188 publications as of September 2017 have presented novel
variations, architectures, optimization algorithms and applications for this class of methods. GANs
are generative models where two neural networks, a Discriminator D and a Generator G compete in a
zero-sum game theory context. The goal of D is to correctly discriminate real samples from synthetic
samples created by G. The goal of G is to create realistic samples that decrease D’s accuracy until
they reach a Nash equilibrium where the Discriminator cannot do better than guessing if samples
are real or not. While GANs have demonstrated their power in applications such as text-to-image
synthesis [13, 18], image-to-image translation [7], video generation [15], and even music generation
[17], applications to healthcare remain scarce.
Besides use cases in medical imaging such as SegAN presented by Xue et al. [16] for medical image
segmentation, two GANs architectures applied to electronic health records (EHR) stand out: the
RCGAN, a Recurrent Conditional GAN capable of generating real-values time series evaluated
with supervised learning tasks [4] and medical GAN (medGAN)[2], an algorithm that can generate
synthetic Electronic Health Records (EHR) matrices of binary or count features using an autoencoder
to learn latent features and force the outputs to discrete variables.
Deep generative models represent an opportunity in biomedical sciences for various applications.
They have been identified as a promising method to release de-identified biomedical data that can
be shared while preserving privacy [1, 2] and can support model learning in supervised setups [4].
GANs also have shown potential for prediction and inference outside of the biomedical realm, with
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papers using the GAN frameworks to predict video frames [11] and others performing adversarially
learned inference [3]. There is little precedent for trying to forecast laboratory test trajectories in an
unsupervised fashion. The benefits of predicting patient-specific laboratory test trajectories could
be significant in drug safety in particular, where laboratory tests and other temporal measurements
represent reliable biomarkers for drug-drug interactions adverse drug reactions, as shown by Tatonetti
et al. [14] with Paroxetine and Pravastatin increasing blood glucose levels and Lorberbaum et al. [9]
with drug-induced QT prolongation. Being able to train drug-specific GAN models would inform the
detection of such events or even quantify the impact of a drug on a particular laboratory test.
Our objective in this paper is to generate continuous time series that display effects of exposure
changes with a simple GAN architecture. More specifically, we focused on drug laboratory effects
(DLEs) – decrease or increase of laboratory test due to a specific drug exposure – in order to
compare real and synthetic time series and their effects on the statistics of pre and during exposure
measurements. To this end, we decided to study the effect of HMG-CoA reductase inhibitors, or
statins, on cholesterol laboratory measurements they are designed to decrease [8]. Our cohort of
interest is therefore exclusively composed of patients exposed to statins. We decided to leave the
inclusion of cholesterol measurements from patients not exposed to statins for future work and focus
here only on the exposure effects. We are aware of the extensive use of recurrent neural networks on
time series in the literature, but having aligned all the time series in our experiments did not justify
their use for the present study.
EHR data are known to be complex due to their multi-modality [6], mixing categorical and continuous
data with semi-structured and free text medical notes. There is no study to our knowledge that
investigates the impact of that complexity when training generative models and how clinically
meaningful cohort stratification can improve the accuracy of synthetic data. The key contributions
of this paper are: (1) Describing a method to normalize laboratory test time series to study drug
laboratory effects (DLEs); (2) Demonstrating that clinically driven deep cohort stratification results in
more accurate GANs; (3) Proposing an unsupervised evaluation method to GAN models by measuring
the predictive power of synthetic laboratory test series.
2 Methods
2.1 Data
Our electronic health records (EHR) data were collected at the New York Presbyterian/Columbia
University Irving Medical Center between 2000 and 2013 with 19.6 million drug prescriptions for
485,306 patients and 473.6 million laboratory test observations. We selected all the patients exposed
to HMG-CoA reductase inhibitors, or statins (ATC code C10AA) at any point in time. For each of
these patients we collected all the total cholesterol measurements (LOINC code 2093-3) they had.
2.2 Pre-processing
For each patient exposed to statins, we annotated the total cholesterol measurements to determine
if they were falling inside or outside a window of continous exposure to a statin with no gap larger
than 30 days. We split these timelines on and off drug into segments of measurements during an
exposure era preceded by measurements off-exposure at most a year before the beginning of the
drug era. Exposure eras without pre-exposure data following these criteria were excluded. In order
to feed our neural networks vectors of fixed length, we performed a linear interpolation weighted
by the measurement dates to have the same number of points before and during drug exposure. In
order not to distort the pattern between before and during drug exposure, we made sure to interpolate
independently the pre-exposure measurements and the during exposure measurements. Finally, for
better training performances with our GANs architecture, we linearly normalized between -1 and 1
all these time series using the 99th percentile values of total cholesterol measurements at any point in
time for patients exposed to statins, which removed potentially erroneous values and extreme outliers.
Values exceeding this range were brought back to -1 if too low and 1 if too high.
2.3 Deep patients stratification
We collected clinical covariates for our cohort in the period before drug exposure: drug prescriptions
in the form of ATC codes and ICD-9 diagnoses code that we grouped by 3-digit codes. We trained a
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deep autoencoder with four encoding layers (256, 128, 64, 32) and four decoding layers on these
binary features before exposure. This approach is analogous to the Deep Patient model [12]. We
then applied the t-SNE algorithm developed by Maaten and Hinton [10] to represent patients in two
dimensions and clustered with spectral clustering.
2.4 Generative Adversarial Network training
We used the mini-batch averaging method proposed by Choi et al. [2] with some notable differences:
the model was performing best when the autoencoder’s encoder layer had the same size as the
input, therefore not compressing but simply identifying meaningful features. We selected a tanh
reconstruction function and evaluated the loss with a mean square error given the continuous nature
of our normalized time series. The generator had a single layer of size 16, and the discriminator had
two layers of sizes 32 and 16. Given the low number of features that we had, we avoided over-fitting
the model by having too many hidden units. Each GAN was trained on 100 epochs and with a batch
size of 10, except for the smallest cluster that was trained with a batch size of 5.
2.5 Evaluation of GAN outputs
Our evaluation process was 2-tiered: first, we evaluated the presence and magnitude of the drug effect
using a paired t-test on the average values before and during drug exposure for each measurement
segment. We defined the effect size as the mean of the differences between both groups of measure-
ments. Second, we evaluated how predictive synthetic time series were as a measure of fidelity to the
real data. To do so, we used the mean square error MSEpre(x, xˆ) as a measure of similarity between
a real time series x and a synthetic one xˆ using the before exposure values only. The predictivity
error was expressed as the mean square error MSEexp(x, xˆ) on the values during exposure only. To
evaluate the predictivity of a set SˆV of V synthetic series for a given set SN of N real series, we
expressed the predictivity error Perr as:
Perr(SN , SˆV ) =
1
N
N∑
k=1
MSEexp(xk, argmin
xˆj∈V
(MSEpre(xk, xˆj))
which is the mean of the predictivity errors from each real series xk with its most similar synthetic
series based on the pre-exposure measurements. For each cluster identified, we compared Perr
between the GAN trained on the whole cohort, and the GAN trained on the cluster of interest. For
each GAN model we generate 10 times more synthetic samples than the largest cluster, and then
sampled as many synthetic time series as there are real ones. The random clusters were obtained with
sampling without replacement and were the same size as the real clusters for each test.
3 Results
We identified 65,563 patients exposed to any statin in the inpatient setting, with a total of 411,880
total cholesterol measurements (average per patient: 8.4, min:1, max:313). After pre-processing
their total cholesterol measurement series, and excluding patients with no measurement during drug
exposure and patient without measurements within a year before exposure, we ended up with 4,830
patients (50.6% females) with an average age at statin exposure of 65.15 (SD: 12.25). Each patient
was associated with one interpolated time series of total cholesterol of 16 points (8 measurements
before, 8 measurements during exposure). No patient had enough data to have more than one
before/during exposure measurement series according to our criteria. Our cohort presented an average
total cholesterol value of 170.6 mg/dL (SD: 56.79) before statin exposure, and 160.7 mg/dL (SD:
50.98) during statin exposure, significantly lower (p < 10−79), compared to the average of 185.3
mg/dL (SD: 50.48) for the 1,345,017 values available in our EHR system. The 99 percentile interval
of total cholesterol for this cohort was [75− 319] mg/dL.
By compressing the 1524 clinical features into 32 dimensions with our deep autoencoder and
representing them in two dimensions using t-SNE, we identified two clearly defined clusters and
one larger cluster that the spectral clustering cut in two. Remarkably, cluster 3 was solely composed
of type 2 diabetes patients. We trained GANs on the total cohort (totalGAN) and on each cluster
(subGANs) and represented the average synthetic time series they generated compared to the real one
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with their standard deviation (Figure 1). We then evaluated the accuracy of subGANs against the
totalGAN using the similarity and prediction MSE described in the Methods section above.
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Figure 1: A. Clustered t-SNE representation of the time series encoded using clinical co-variates B.
Comparison of the average time series generated by the GANs trained on each cluster with the real
time series.
Table 1: Predictivity error Perr (± SD)
Clinical Clusters Random Clusters
Cluster subGAN totalGAN p-value subGAN totalGAN p-value
Cluster 0 0.13 (±0.22) 0.16 (±0.28) 5.7e-4 0.27 (±0.39) 0.16 (±0.27) 2.0e-303
Cluster 1 0.15 (±0.27) 0.16 (±0.26) 1.5e-1 0.30 (±0.45) 0.16 (±0.26) 2.2e-308
Cluster 2 0.11 (±0.21) 0.22 (±0.35) 3.9e-5 0.24 (±0.40) 0.15 (±0.26) 1.1e-21
Cluster 3 0.12 (±0.20) 0.15 (±0.24) 3.9e-4 0.28 (±0.38) 0.16 (±0.27) 1.5e-144
The real data of each cluster was significantly better predicted by the subGANs than by the totalGAN
for all clusters except for Cluster 1. Moreover, subGANs trained on random clusters of identical size
significantly performed worse than the clinically relevant ones (Table 1), hinting at the importance of
clinical variables.
4 Discussion
In this paper we presented an unsupervised framework to evaluate generative adversarial networks
for the prediction of drug-induced laboratory test trajectories. This framework is applicable to any
time series affected by a known exposure factor. We defined a similarity measure to align synthetic
time series to real ones before exposure and a metric to evaluate the prediction performances of
synthetic time series during the exposure period. Further, we demonstrated that clinical variables
can be integrated to identify meaningful clusters that produce significantly more accurate GANs
with regard to exposure trajectory prediction. By using a deep autoencoder, we hint at the potential
for integrating neural network-based compressed representations of patients into conditional GANs
architectures while keeping evaluations completely unsupervised. Such architectures would also
direct the synthetic data generation to ensure an increased similarity with the real data. Finally, more
work needs to be conducted to evaluate how to sample efficiently from the learned distributions to go
further in the trajectory prediction process and provide probability densities rather than a prediction
error.
5 Conclusion
In conclusion, we presented a novel unsupervised framework for evaluating the use of generative
adversarial model on clinical time series and the prediction of their trajectory after a known exposure.
In future work, we will integrate the patient deep representation into the GAN architecture to improve
predictive power.
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A Total cholesterol distributions
In this section, we provide the total cholesterol distributions’ statistics and figures for the different
cohorts mentions in the Results section. Normal ranges for total cholesterol (LOINC 2093-3) are
below 200 mg/dL. Between 200 and 240 mg/dL the level is considered to be borderline high. Total
cholesterol is considered to be high for values above 240 mg/dL. As mentioned in the Results
section, we collected a total of 411,880 total cholesterol measurements in the period of interest of
our retrospective study. The minimal value measured was 0.0 and the maximal value was 3368
mg/dL, yielding an average of 184.6 mg/dL (± 45.58). To remove outliers in that study, we only
considered the 99 percentiles as represented in Figure S1 showing the density estimate distribution of
total cholesterol values over all patients between 2000 and 2013.
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Figure S1. 99 percentiles of the total cholesterol distribution for all patients in our clinical data
warehouse between 2000 and 2013, with total cholesterol (LOINC 2093-3) normal ranges.
Figure S2. represents the laboratory test measurements after linear interpolation and linear normaliza-
tion using the 99 percentile extremal values as normalization bounds, for the complete cohort for all
time points, for the measurements before exposure, and the measurement during exposures, and the
four sub clusters identified using clinical variables as described in the Methods section 2.3.
B Generated time series figures
In this subsection, we present randomly selected real time series from each of the four sub clusters
with the synthetic time series from the GAN trained on the whole cohort (totalGAN), and the GAN
trained on the specific cluster (subGAN) that were the closest before exposure to provide visualize
cues about the predictive errors (Figure S3-6).
6
Normalized total cholesterol measurements distributions
TOTAL PRE EXPOSURE DURING EXPOSURE
Cluster 0
Cluster 1
Cluster 2
Cluster 3
Complete statin cohort
Figure S2. Normalized total cholesterol measurements for the complete statin cohort, and the 4
sub-clusters, overall (TOTAL), before exposure, and during exposure to statins.
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Figure S3. Cluster 0.
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Figure S4. Cluster 1.
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Figure S5. Cluster 2.
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Figure S6. Cluster 3.
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